Signify Research’s take on contextflow’s partnership with RevealDx

Presse Actualités

2023-07-24

Signify Research is widely-respected in our industry for its in-depth analyses of current market trends. That’s why we’re honored to have been featured in the article titled « contextflow Reveals Its Hand« , discussing the why behind our recent partnership announcment with RevealDx.

RevealDx developed RevealAIöLung, the world’s first CADx software for the characterization of lung nodules to receive the CE Mark. The company recently completed its pivotal clinical trial which demonstrated significant improvement in both early detection of malignant nodules and reduction in false positive nodules in both screening and incidental cohorts. By integrating this patented technology into clinical routine, healthcare providers can reduce unnecessary procedures, cost and stress for patients with lung nodules.

Signify Research’s take? « contextflow’s SEARCH solution remains unique in the market today. No other vendor offers a similar value proposition. Further, a study published in the Journal of the American College of Radiology highlighted Reveal DX’s ability to help clinicians diagnose lung cancer sooner with improved specificity. By bringing these capabilities together, both vendors have created a comprehensive lung cancer solution for CT imaging that can, on paper, outcompete most of its competitors. »  

RevealDx and contextflow team up to improve lung cancer screening in the EU via enhanced nodule characterization

Presse Actualités

2023-07-24

RevealDx appoints contextflow as its exclusive distributor in the European Union and selected territories. The companies also announce trial installation discounts for select customers.

Chest specialists RevealDx and contextflow announced today an agreement for exclusive distribution of RevealDx’ products in the EU and other selected territories. The companies will be launching their integrated solution at the upcoming IASLC World Conference on Lung Cancer in Vienna in August. 

RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of lung nodules to receive the CE Mark. The company recently completed its pivotal clinical trial which demonstrated significant improvement in both early detection of malignant nodules and reduction in false positive nodules in both screening and incidental cohorts.* By integrating this patented technology into clinical routine, healthcare providers can reduce unnecessary procedures, cost and stress for patients with lung nodules. *publication Fall 2022

contextflow is an industry leader in AI-based medical devices for radiologists evaluating chest CTs. Its core technology is SEARCH Lung CT, a clinical decision support system that automatically detects, quantifies and visualizes key disease patterns and lung nodules in CTs of the lungs over time, displaying relevant information directly in the radiologist’s PACS viewer. The tool is relevant for the analysis of many suspected diseases, including interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD) and lung cancer. By including RevealDx’ lung nodule characterization technology into SEARCH Lung CT, contextflow strengthens its capabilities even further in the area of lung cancer screening by providing not just quantifications but also classification of lung nodule types. 

Integrating RevealDx’ nodule characterization technology into SEARCH Lung CT was a logical next step for both sides. As Chris Wood, CEO of RevealDx says, “We are thrilled to be partnering with contextflow. They have developed the most comprehensive set of tools for reading chest CT available today. Adding RevealAI-Lung to their system makes it far and away the best solution to efficiently and accurately interpret these challenging lung cancer cases.”

Markus Holzer, CEO of contextflow continues, “The RevealAI-Lung software has been well integrated into our software, creating a seamless experience for users. We recently launched our nodule detection software and quickly realized that characterization of nodules is essential to make a significant impact on patient care. Partnering with RevealDx adds a layer of detail that we feel will become indispensable for reducing false positives and false negatives during lung cancer screening as well as in standard clinical routine.”

To schedule a virtual demo or book an appointment at IASLC, contact sales@contextflow.com. 

About RevealDx

RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of lung nodules to receive the CE Mark. RevealAI-Lung has been validated in clinical studies that show improvement in diagnostic precision using our patented methods.  Results demonstrate the software can significantly accelerate lung cancer diagnosis and reduce unnecessary procedures. https://reveal-dx.com/

Softway Medical Group partners with contextflow to bring comprehensive AI support for lung pathologies to France

Presse Actualités

2023-07-24

October 6, 2022 – With this partnership announced in advance of JFR 2022, Softway Medical – the French leader in health information systems – augments its offer for medical imaging professionals. 

By making contextflow SEARCH Lung CT accessible from its applications, Softway Medical Group is now in a position to offer its clients a complete clinical decision support solution for interstitial lung diseases (ILD), COPD and lung cancer. This is the first time that such a solution will be offered to medical imaging professionals in France. 

For users, the benefits are significant. In a recent clinical study at the Medical University of Vienna, average report reading time decreased by 31% when an earlier version of contextflow SEARCH Lung CT was present for use.*

contextflow SEARCH Lung CT, a comprehensive solution integrated directly into the radiologist’s workflow

contextflow SEARCH Lung CT is now available on Softway Medical’s SYNAPSE PACS and will soon be fully integrated into the easIA platform. The results of the analyses of this new AI algorithm will be available to the radiologist directly in the worklist of the RIS ONE MANAGER and VENUS.

This is a pragmatic response to the challenges faced by radiologists seeking to increase their productivity and the relevance of their diagnoses for the benefit of patients. « We are very pleased with this partnership with contextflow, an inspiring company with whom we share a common vision of health information systems that should serve professionals without replacing them. Our teams are working hand in hand to integrate the solution with our applications, » says Jean-Baptiste Franceschini, Marketing and Communication Director of Softway Medical Group.

The easIA platform was designed to organize, secure and centralize exchanges between the RIS and partner AI engines.

Interested parties can meet contextflow at JFR 2022 at the innovation station at Softway Medical’s stand 1N07.

*Recent clinical study conducted at the Medical University of Vienna: researchers observed an average time saving of 31% in reading studies when using

earlier version of SEARCH Lung CT.

About Softway Medical

Committed to providing healthcare professionals with the best digital solutions, SOFTWAY MEDICAL, the French leader in healthcare software, continues to innovate in order to contribute to making France one of the standard bearers of e-health. As a host and integrator of solutions for healthcare professionals for over 25 years, SOFTWAY MEDICAL’s mission is to enable

physicians to make informed decisions and fully exploit their capabilities. Because in the field of health, nothing can replace the discernment of human intelligence; thus, SOFTWAY MEDICAL considers technology and data management as a means to increase the potential of anyone who uses it. Its innovations have only one objective, to allow each of its users to fully exploit their capacities and to make informed decisions in their daily work in the interest of the patient. This profession of faith has enabled the company to become the leading French Hospital Information Systems (HIS) publisher in France. https://www.softwaymedical.fr/